Sacituzumab govitecan trials for Breast cancer

All Sacituzumab govitecan trials · All Breast cancer trials

Phase breakdown

Recruiting trials studying Sacituzumab govitecan for Breast cancer

• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
  NCT03424005 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 53 locations
• Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
  NCT04434040 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy
  NCT05770531 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer
  NCT06665178 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan
  NCT06236269 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response
  NCT07582887 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
  NCT05601440 · Phase: Phase 2 · Ages: No age limits stated · Sex: All (male and female) · 10 locations
• NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
  NCT06081244 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Female · 43 locations
• Organoid-based Functional Precision Therapy for Advanced Breast Cancer
  NCT06102824 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
  NCT04468061 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 15 locations
• Sacituzumab Govitecan In TNBC
  NCT04230109 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer
  NCT06462092 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
  NCT06238921 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Scalp Cooling in MBC
  NCT04986579 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
  NCT06263543 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
  NCT06409390 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
  NCT07011654 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
  NCT03606967 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
  NCT07461454 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: Female · 1 location

Common questions

How many trials study Sacituzumab govitecan for Breast cancer?

19 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.